Patient-reported outcomes from a multicenter, randomized, vehicle-controlled clinical study of MAS063DP (Atopiclair™) in the management of mild-to-moderate atopic dermatitis in adults

Journal of Dermatological Treatment

Volumn 19, Issue 6, 2008, Pages 327-332

  Abramovits, William ^a,b   Hebert, Adelaide A ^c   Boguniewicz, Mark ^d   Kempers, Steven E ^e   Tschen, Eduardo ^f   Jarratt, Michael T ^g   Lucky, Anne W ^h   Cornelison, Raymond L ⁱ   Swinyer, Leonard J ^j   Jones, Terry M ^k  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Dermatology Treatment and Research Center   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d Children's Hospital Colorado   (United States)

^e Minnesota Clinical Study Center   (United States)

^f Academic Dermatology Associates   (United States)

^g DermResearch Inc   (United States)

^h Dermatology Research Associates   (United States)

ⁱ UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^j Dermatology Research Center   (United States)

^k J and S Studies   (United States)

more..

Author keywords

Atopic dermatitis; MAS063DP; Non steroidal; Topical treatment

Indexed keywords

ANTIPRURITIC AGENT; ATOPICLAIR; ATOPLICAIR; MAS 063 DP; UNCLASSIFIED DRUG; ZARZENDA;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERCEPTION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DERMATITIS, ATOPIC; DERMATOLOGIC AGENTS; DIETARY FATS; DOUBLE-BLIND METHOD; FEMALE; GLYCYRRHETINIC ACID; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PLANT EXTRACTS; SEVERITY OF ILLNESS INDEX; TEXAS; TREATMENT OUTCOME;

EID: 56549094820     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630802232799     Document Type: Article

References (37)

1. Su JC, Kemp AS, Varigos GA, Nolan TM. Atopic eczema: Its impact on the family and financial cost. Arch Dis Child. 1997;76:159-62.
2. Drake L, Prendergast M, Maher R, Breneman D, Korman N, Satoi Y, et al. The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis. J Am Acad Dermatol. 2001;44(1 suppl):s65-72.
3. Holm EA, Esmann S, Jemec GB. The handicap caused by atopic dermatitis - sick leave and job avoidance. J Eur Acad Dermatol Venereol. 2006;20:255-9.
4. Abramovits W. Atopic dermatitis. J Am Acad Dermatol. 2005;53(1 suppl 1):s86-93.
5. Abramovits W. Atopic dermatitis. J Am Acad Dermatol. 2005;53(1 suppl 1):s70-7.
6. Tofte SJ, Hanifin JM. Current management and therapy of atopic dermatitis. J Am Acad Dermatol. 2001;44(1 suppl 1):s13-16.
7. Boguniewicz M, Nicol N. Conventional therapy for atopic dermatitis. Immunol Allergy Clin North Am. 2002;22:107-24.
8. Ellis C, Luger T, Abeck D, Allen R, Graham-Brown RA, De Prost Y, et al. International Consensus Conference on Atopic Dermatitis II (ICCAD II): Clinical update and current treatment strategies. Br J Dermatol. 2003;148(suppl 63):s3-10.
9. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, et al. Guidelines of care for atopic dermatitis. J Am Acad Dermatol. 2004;50:391-404.
10. Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1-15.
11. Fleischer A. Treatment of atopic dermatitis: Role of tacrolimus ointment as a topical noncorticosteroidal therapy. J Allergy Clin Immunol. 1999;104(3 part 3):s126-30.
12. Qureshi AA, Fischer MA. Topical calcineurin inhibitors for atopic dermatitis: Balancing clinical benefit and possible risks. Arch Dermatol. 2006;142:633-57.
13. Abramovits W, Gover MD, Gupta AK. Atopiclair nonsteroidal cream. Skinmed. 2005;4:369.
14. Amagaya S, Sugishita E, Ogihara Y, Ogawa S, Okada K, Aizawa T. Comparative studies of the stereoisomers of glycyrrhetinic acid on anti-inflammatory activities. J Pharmacobiodyn. 1984;7:923-8.
15. Bombardelli E, Curri SB, Della Loggia R, Del Negor P, Tubaro A, Gariboldi P. Anti-inflammatory activity of 18-β-glycyrrhetinic acid in Phytosome® form. Fitoterapia. 1989;60(suppl 1):s29-39.
16. Monder C, White PC. 11-beta-hydroxysteroid dehydrogenase. Vitam Horm. 1993;47:187-271.
17. MacKenzie MA, Hoefnagels WH, Jansen RW, Benraad TJ, Kloppenborg PW. The influence of glycyrrhetinic acid on plasma cortisol and cortisone in healthy young volunteers. J Clin Endocrinol Metab. 1990;70:1637-43.
18. Teelucksingh S, Mackie AD, Burt D, McIntyre MA, Brett L, Edwards CR. Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid. Lancet. 1990;335:1060-3.
19. Kroes BH, Beukelman CJ, van den Berg AJ, Wolbink GJ, van Dijk H, Labadie RP. Inhibition of human complement by beta-glycyrrhetinic acid. Immunology. 1997;90:115-20.
20. Shin YW, Bae EA, Lee B, Kim JA, Kim YS. In vitro and in vivo antiallergic effects of Glycyrrhiza glabra and its components. Planta Med. 2007;73:257-61.
21. Lee YM, Hirota S, Jippo-Kanemoto T, Kim HR, Shin TY, Yeom Y, et al. Inhibition of histamine synthesis by glycyrrhetinic acid in mast cells cocultured with Swiss 3T3 fibroblasts. Int Arch Allergy Immunol. 1996;110:272-7.
22. Kang OH, Kim JA, Choi YA, Park HJ, Kim DK, An YH, et al. Inhibition of interleukin-8 production in the human colonic epithelial cell line HT-29 by 18 beta-glycyrrhetinic acid. Int J Mol Med. 2005;15:981-5.
23. Homma M, Minami M, Taniguchi C, Oka K, Morita S, Niitsuma T, et al. Inhibitory effects of lignans and flavonoids in saiboku-to, a herbal medicine for bronchial asthma, on the release of leukotrienes from human polymorphonuclear leukocytes. Planta Med. 2000;66:88-91.
24. Maffei Facino R, Carini M, Aldini G, Bombardelli E, Morazzoni P, Morelli R. Free radicals scavenging action and anti-enzyme activities of procyanidines from Vitis vinifera. A mechanism for their capillary protective action. Arzneimittelforschung. 1994;44:592-601.
25. Weindl G, Schaller M, Schäfer-Korting M, Korting HC. Hyaluronic acid in the treatment and prevention of skin diseases: Molecular biological, pharmaceutical and clinical aspects. Skin Pharmacol Physiol. 2004;17:207-13.
26. Grassi L, Moretti M, Bisetti A. Un nuovo farmaco mucoattivo con attivita' anti-proteasica: la Telmesteina. Riv Ital Biol Med. 1992;12:67-74.
27. Data on file Sinclair Pharmaceuticals Ltd, Goldalming, United Kingdom, March 2005.
28. Abramovits W, Boguniewicz M. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol. 2006;5:236-44.
29. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 1980;suppl 92:44-7.
30. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1989;144:13-14.
31. Wahlgren CF. Itch and atopic dermatitis: An overview. J Dermatol. 1999;26:770-9.
32. Abeck D, Strom K. Optimal management of atopic dermatitis. Am J Clin Dermatol. 2000;1:41-6.
33. Kang S, Lucky AW, Pariser D, Lawrence I, Hanifin JM. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001;44:58-64.
34. Zuberbier T, Orlow SJ, Paller AS, Taïeb A, Allen R, Hernanz-Hermosa JM, et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol. 2006;118:226-32.
35. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142:931-6.
36. Schiffner R, Schiffner-Rohe J, Landthaler M, Stolz W. How large is the loss of effectiveness of a treatment modality between 'theory' and 'practice'? An evaluation of health economics factors in a study of 1281 patients treated with ambulatory balneophototherapy. Hautarzt. 2002;53:22-9.
37. Fischer G. Compliance problems in paediatric atopic eczema. Australas J Dermatol. 1996;37:10-13.